RxDoctor Payments Data

Mandeep Ayer, MD

Internal Medicine · Los Gatos, CANPI 1205817111

Payments from drug & device makers

$1,181in general payments, 2019–2025

Across 55 payments — averaging $21.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$304
  • Novo Nordisk$155
  • Medtronic$115
  • GSK$107
  • Amgen$106
  • AstraZeneca$98
  • plus $296 from 8 others

What the payments were for

  • Food & beverage$1,16298%
  • Education$192%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,181 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$265,529
Medicare patients
374
Services billed
3,098

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban98$107,324
OzempicSemaglutide75$70,408
JanuviaSitagliptin Phosphate43$61,070
MounjaroTirzepatide28$30,553
XareltoRivaroxaban27$25,050
JardianceEmpagliflozin12$21,708
TradjentaLinagliptin13$19,048
ProliaDenosumab11$18,768
TrulicityDulaglutide11$14,002
Repatha SureclickEvolocumab12$8,911
Atorvastatin Calcium620$6,946
Levothyroxine Sodium473$6,803
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide165$5,808
SynthroidLevothyroxine Sodium63$5,804
Buprenorphine13$5,060

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$304$108,753131 claims
Novo NordiskOzempic$155$70,40875 claims
MerckJanuvia$35$61,07043 claims
Lilly USA, LLCMounjaro, Trulicity$60$44,55539 claims
Johnson & JohnsonXarelto$18$25,05027 claims
AmgenProlia$106$18,76811 claims
AbbVieSynthroid$41$5,80463 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Los Gatos

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →